202 related articles for article (PubMed ID: 17600384)
41. Simultaneous ultra-high performance liquid chromathograpy-electrospray ionization-quadrupole-time of flight mass spectrometry quantification of endogenous anandamide and related N-acylethanolamides in bio-matrices.
Ottria R; Ravelli A; Gigli F; Ciuffreda P
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 May; 958():83-9. PubMed ID: 24705535
[TBL] [Abstract][Full Text] [Related]
42. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.
Rubio M; McHugh D; Fernández-Ruiz J; Bradshaw H; Walker JM
Neurosci Lett; 2007 Jun; 421(3):270-4. PubMed ID: 17574742
[TBL] [Abstract][Full Text] [Related]
43. Quantitative LC-MS/MS analysis of arachidonoyl amino acids in mouse brain with treatment of FAAH inhibitor.
Han B; Wright R; Kirchhoff AM; Chester JA; Cooper BR; Davisson VJ; Barker E
Anal Biochem; 2013 Jan; 432(2):74-81. PubMed ID: 23044255
[TBL] [Abstract][Full Text] [Related]
44. Biosynthetic pathways of the endocannabinoid anandamide.
Okamoto Y; Wang J; Morishita J; Ueda N
Chem Biodivers; 2007 Aug; 4(8):1842-57. PubMed ID: 17712822
[TBL] [Abstract][Full Text] [Related]
45. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
46. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
47. Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex.
Steffens M; Feuerstein TJ; van Velthoven V; Schnierle P; Knörle R
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):432-6. PubMed ID: 14566450
[TBL] [Abstract][Full Text] [Related]
48. Plasma endocannabinoid levels in multiple sclerosis.
Jean-Gilles L; Feng S; Tench CR; Chapman V; Kendall DA; Barrett DA; Constantinescu CS
J Neurol Sci; 2009 Dec; 287(1-2):212-5. PubMed ID: 19695579
[TBL] [Abstract][Full Text] [Related]
49. Recent advances in the synthesis of endocannabinoid related ligands.
Razdan RK; Mahadevan A
Chem Phys Lipids; 2002 Dec; 121(1-2):21-33. PubMed ID: 12505687
[TBL] [Abstract][Full Text] [Related]
50. The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.
Fowler CJ
Fundam Clin Pharmacol; 2006 Dec; 20(6):549-62. PubMed ID: 17109648
[TBL] [Abstract][Full Text] [Related]
51. Endocannabinoids and non-endocannabinoid fatty acid amides in cirrhosis.
Ying-Ying Y; Lin HC
Liver Int; 2010 Jul; 30(6):780-1. PubMed ID: 20408944
[No Abstract] [Full Text] [Related]
52. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
53. Endogenous cannabinoids: structure and metabolism.
Bisogno T
J Neuroendocrinol; 2008 May; 20 Suppl 1():1-9. PubMed ID: 18426492
[TBL] [Abstract][Full Text] [Related]
54. In-tube solid-phase microextraction directly coupled to tandem mass spectrometry for anandamide and 2-arachidonoylglycerol determination in rat brain samples from an animal model of Parkinson's disease.
Oliveira IGC; Souza ID; Nascimento GCD; Del Bel E; Queiroz MEC
J Chromatogr A; 2021 Jan; 1636():461766. PubMed ID: 33316562
[TBL] [Abstract][Full Text] [Related]
55. Endocannabinoids: synthesis and degradation.
Di Marzo V
Rev Physiol Biochem Pharmacol; 2008; 160():1-24. PubMed ID: 18481028
[TBL] [Abstract][Full Text] [Related]
56. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain.
Astarita G; Ahmed F; Piomelli D
J Lipid Res; 2008 Jan; 49(1):48-57. PubMed ID: 17957091
[TBL] [Abstract][Full Text] [Related]
57. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues.
Koga D; Santa T; Fukushima T; Homma H; Imai K
J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):7-13. PubMed ID: 9106024
[TBL] [Abstract][Full Text] [Related]
58. Determination of the endocannabinoid anandamide in human plasma by high-performance liquid chromatography.
Schmidt A; Brune K; Hinz B
Biomed Chromatogr; 2006 Apr; 20(4):336-42. PubMed ID: 16189813
[TBL] [Abstract][Full Text] [Related]
59. Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues.
El Fangour S; Balas L; Rossi JC; Fedenyuk A; Gretskaya N; Bobrov M; Bezuglov V; Hillard CJ; Durand T
Bioorg Med Chem Lett; 2003 Jun; 13(12):1977-80. PubMed ID: 12781177
[TBL] [Abstract][Full Text] [Related]
60. A micro salting-out assisted liquid-liquid extraction combined with ultra-high performance liquid chromatography tandem mass spectrometry to determine anandamide and 2-arachidonoylglycerol in rat brain samples.
Oliveira IGC; Queiroz MEC
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1158():122351. PubMed ID: 32882531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
